Clinical trials: SARS-COV2 Virus
Covid-19, Drug Effect
New Treatment for COVID-19 Using Ethanol Vapor Inhalation .
Since ARDS is a major complication of COVID - 19 with subsequent formation of non-cardiogenic pulmonary edema , worsening the oxygenation of the patients and foamy and even bloody sputum formation, so the idea is to use alcohol…
- Trial name
- NCT04554433
- Testing
- Ethanol with Asprin
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Covid-19
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients
Hydroxychloroquine, a derivative of chloroquine (an antimalarial drug) with a weak immunosuppressive effect, is prescribed by some teams alone or in combination with azithromycin.
- Trial name
- MG-COVID (NCT04371406)
- Testing
- Hydroxychloroquine and Azithromycin, Azinc
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Sars-CoV2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID-19, Sars-CoV2, Pneumonia
- Trial name
- NCT04463004
- Testing
- Mavrilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
Covid19
The Salivary Raman COVID-19 Fingerprint
The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic.
- Trial name
- NCT04583306
- Testing
- Raman analysis of saliva, characterization of the Raman database and building of the classification model
- Where
- 5 sites in Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Acute Respiratory Distress Syndrome, Covid19
Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19
Acute myocardial injury has been a finding of variable frequency among patients diagnosed with COVID-19. It is now recognized that cTnI levels are strongly associated with increased mortality.
- Conditions
- Acute Respiratory Distress Syndrome, Covid19, Myocardial Injury
- Trial name
- PREMIER (NCT04760821)
- Testing
- Trimetazidine
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Ministry of Health, Brazil
SARS-CoV-2
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People
This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China
- Trial name
- NCT05549206
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Long COVID, Post COVID-19 Condition
Effect of Hi-OxSR for the Treatment of Post COVID Condition
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction.
- Conditions
- Long COVID, Post COVID-19 Condition, Post Acute Sequelae of COVID-19
- Trial name
- RECLAIM-HiOxSR (NCT06928506)
- Testing
- Hi-OxSR device, Hi-Ox device
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
SARS-CoV-2 Serological Status, SARS-CoV-2 Seroprevalence
Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)
COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden increase of…
- Trial name
- SeroCoV-HUS (NCT04441684)
- Testing
- Blood sample for serological test
- Where
- France
- Volunteers
- 1,466 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Postural Orthostatic Tachycardia Syndrome, Post Acute Sequelae of SARS CoV 2 Infection
NC Testing in LC & POTS
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction.
- Trial name
- NCT05914649
- Testing
- IV normal saline (999 mL infusion), IV normal saline (50 mL infusion)
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Calgary
COVID-19
Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)
The 2019 Coronavirus disease outbreak (COVID-19) was first reported at the end of 2019 in Wuhan China as a severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection.
- Trial name
- NCT05172193
- Testing
- SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
- Where
- 7 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
SARS-CoV-2 Infection
Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients
In this study nasal fluid (mucosal lining fluid), nose and throat swabs and blood was collected from patients with a confirmed SARS-CoV-2 infection who remained in home isolation, as well as from their household contacts who…
- Trial name
- MuCo (NCT04590352)
- Testing
- nasopharyngeal and throat swab, collection of mucosal lining fluid, blood collection via fingerprick
- Where
- Netherlands
- Volunteers
- 187 people
- Sponsor
- Radboud University Medical Center
Long COVID
A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.
This is a multi-center, outcome assessor-blinded, practical randomized controlled trial, aiming to compare the actual clinical effectiveness of individualized traditional Chinese medicine and conventional Western medicine in the…
- Trial name
- NCT06095258
- Testing
- Traditional Chinese medicine treatment, Western medicine treatment
- Volunteers
- 162 people
- Sponsor
- Chinese University of Hong Kong
Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19 and Anti-CD14 Treatment Trial
This study aims to address the following objectives: 1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms of…
- Trial name
- CaTT (NCT04391309)
- Testing
- anti-CD14, remdesivir
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815…
- Trial name
- NextCOVE (NCT05815498)
- Testing
- mRNA-1283.222, mRNA-1273.222, mRNA-1283.815
- Where
- 230 sites in United States, Canada and 2 more
- Volunteers
- 13,553 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Coronavirus Disease 2019
Fostamatinib for Hospitalized Adults With COVID-19
Background: COVID-19 is a new disease caused by SARS-CoV-2 that was identified in 2019. Some people who get sick with COVID-19 become ill requiring hospitalization. There are some medicines that may help with recovery.
- Trial name
- NCT04579393
- Testing
- fostamatinib
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sars-CoV2, Serum; Disease
Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue.
- Trial name
- PRO-SERO-COV (NCT04426006)
- Testing
- PRO-SERO-COV
- Where
- France
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Institut Bergonié
Chronic Hemodialysis Patients, Caregivers of Chronic Hemodialysis Patients
SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study
Background: The preventive containment measures implemented in the COVID-19 pandemic are not feasible in chronic hemodialysis patients (HD) who need to attend their dialysis sessions 3 times a week.
- Trial name
- SeroCOVIDial (NCT04420338)
- Testing
- Blood sample, Serum tube collection
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis
The Corona Study of Middle Norway
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during…
- Conditions
- SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis, SARS CoV 2 Infection
- Trial name
- CUT COVID-19 (NCT05638178)
- Testing
- No intervention
- Where
- 5 sites in Norway
- Volunteers
- 223 people
- Sponsor
- St. Olavs Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.